BioCryst Pharma (BCRX) Misses Q1 EPS by 303c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $7.82 +0.90%
Revenue Growth %: +3.9%
Financial Fact:
Total revenues: 7.76M
Today's EPS Names:
SICP, MNSB, CFFI, More
Revenue Growth %: +3.9%
Financial Fact:
Total revenues: 7.76M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($2.98), $3.03 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $156.41 million versus the consensus estimate of $151.66 million.
GUIDANCE:
BioCryst Pharma sees FY2026 revenue of $635-660 million, versus the consensus of $650.2 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Tractor Supply (TSCO) Tops Q3 EPS by 3c; offers guidance
- Roper Technologies (ROP) Tops Q3 EPS by 10c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
